Acarix AB (publ)
ACIXF
Other OTC0.03
USD
- -
- -
ISIN
SE0009268717
Return %
Stock
S&P500
1Y
-18.18
26.84
3Y
92.86
77.03
5Y
-10.00
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Aamir Mahmood
- Full Time Employees
- 8
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- World Trade Center Malmö Sweden 211 19
- IPO Date
- Dec 7, 2022
- Website
- acarix.com
- Similar Companies
- Business
- Acarix AB (publ) develops and commercializes the CADScor System, a point-of-care diagnostic aid for rapid, non-invasive risk stratification of significant coronary artery disease (CAD) in patients presenting with chest pain or shortness of breath; the system employs highly sensitive acoustics to detect turbulent coronary blood flow and myocardial movements, coupled with advanced AI-driven computational processing and algorithms to generate a patient-specific CAD-score within less than eight minutes, enabling physicians to rule out hemodynamically significant CAD with at least 96% negative predictive value prior to more invasive procedures. Founded in 2009 and headquartered in Malmö, Sweden, the company operates through subsidiaries including Acarix USA Inc. in Oklahoma City, Acarix A/S in Hellerup, Denmark, Acarix LTD in Stockport, United Kingdom, and Acarix GmbH in Köln, Germany (under liquidation); it markets the CE-marked and FDA De Novo-cleared CADScor System, along with associated single-use patches for signal detection, primarily to healthcare providers in outpatient and inpatient settings across the Nordic countries, United Kingdom, Germany, Switzerland, Austria, Mauritius, United States, and recently the Middle East and North Africa (MENA) region. The company targets cardiologists, primary care physicians, and emergency departments seeking to reduce unnecessary catheterizations, supported by over 15 years of R&D, 45 patents, and clinical validation from studies involving more than 6,000 patients, with the device used in over 47,000 assessments to date. Recent developments include substantial U.S. market expansion in 2024 with a 333% increase in CADScor System placements (14 systems delivered, including 13 in the U.S.), an 88% surge in patch sales revenue, and gross margins improving to 88%; a favorable U.S. CMS ruling for fixed standalone reimbursement of the CADScor System in outpatient settings, positioning for accelerated 2025 growth; strategic partnerships such as with Geo-Med, LLC to reach U.S. Veterans and Department of Defense, MED Management to enhance German outpatient cardiology access via insurer networks, and agreements for clinical studies with major U.S. health systems like the largest Oklahoma-owned provider; a first major order valued at 1.35 million SEK from a MENA distributor in July 2025, marking entry into that region; sales of nine systems and 500 patches to a multi-state U.S. healthcare provider; a 27% reduction in operating costs; and ongoing efforts in reimbursement advancement, clinical validation, and financial sustainability as detailed in the 2024 year-end report.
Acarix AB (publ) (ACIXF) Q1 2026 Earnings Call Prepared Remarks Transcript
Acarix AB (publ) (ACIXF) Q3 2025 Earnings Call Prepared Remarks Transcript
Acarix AB (publ) publishes Interim Report, April - June 2024